Gujarat Kidney And Super Speciality Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
GKSL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The company reported strong growth for FY26 with consolidated revenue more than doubling to Rs 8,201.34 Lacs from Rs 4,024.21 Lacs in FY25 (104% growth). Consolidated PAT grew 77% to Rs 1,681.18 Lacs from Rs 949.94 Lacs. Standalone revenue grew 14% to Rs 4,010.02 Lacs with PAT up 8.7% to Rs 990.14 Lacs. The significant jump in consolidated numbers is due to addition of multiple subsidiaries (Raj Pathology, Gujarat Surgical Hospital, Surya Hospital, Harmony Medicare, Parekh's Hospital, Patel Multispeciality Hospital, and others). The company raised Rs 25,080 Lacs through equity share issuance, spending Rs 3,330 Lacs on share issue expenses. Auditors issued unmodified (clean) reports for both standalone and consolidated results. Operating cash flow turned negative at Rs 745.86 Lacs standalone and Rs 386.17 Lacs consolidated. The board deferred CEO appointment and will seek shareholder approval for variation in IPO objects.
Revenue doubling on consolidated basis indicates successful integration of new subsidiaries, though standalone operations showed modest growth. The large equity raise improves balance sheet strength but significantly dilutes EPS from Rs 1.79 to Rs 1.59 on standalone basis. Negative operating cash flow warrants monitoring.